TRAIL-R2 (DR5) Recombinant Rabbit Monoclonal Antibody (102), PE, Invitrogen™

Description

• Preparation: This antibody was obtained from a rabbit immunized with purified, recombinant Human TRAIL-R2 (DR5) (Met1-Glu182) and conjugated with PE under optimum conditions, the unreacted PE was removed
• Storage: This antibody can be stored at 2C-8C for twelve months without detectable loss of activity
• Protected from prolonged exposure to light
• Do not freeze! Sodium azide is toxic to cells and should be disposed of properly
• Flush with large volumes of water during disposal
• DR5 (Apo2, TRAIL-R2, TRICK2, KILLER) is a recently identified death domain containing receptor for TRAIL, which mediates TRAIL induced apoptosis
• DR5 is a member of the TNF-receptor superfamily, and contains an intracellular death domain
• DR5 can be activated by tumor necrosis factor-related apoptosis inducing ligand (TNFSF10/TRAIL/APO-2L), and transduces an apoptosis signal
• Studies with FADD-deficient mice suggested that FADD, a death domain containing adaptor protein, is required for the apoptosis mediated by DR5
• Two transcript variants encoding different isoforms of DR5 and one non-coding transcript have been found
• Overexpression of DR5 induces apoptosis and activates NF-kappa-B
• DR5 is expressed in a number of cell types, and to particularly high levels in lymphocytes and spleen
• Diseases associated with DR5 dysfunction include squamous cell carcinoma, and diffuse infiltrative lymphocytosis syndrome.